Literature DB >> 27401563

Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniae.

M Figueira1, P Fernandes2, S I Pelton3.   

Abstract

Solithromycin (CEM-101) is a "fourth-generation" macrolide, as it has three binding site and is acid stable. The three binding sites confer activity against bacteria resistant to the older macrolides and ketolides, including multidrug-resistant Streptococcus pneumoniae and nontypeable Haemophilus influenzae (NTHi). The objective of this study was to evaluate solithromycin pharmacokinetics (PK), middle ear fluid (MEF) concentrations, and microbiologic efficacy in a chinchilla model of experimental otitis media (EOM) due to strains of S. pneumoniae or NTHi. Plasma PK (maximum concentration of drug in serum [Cmax] and area under the concentration-time curve from 0 to 24 h [AUC0-24]) and middle ear fluid (MEF) concentrations were determined. Isolates with specified antimicrobial susceptibility patterns were inoculated directly into the middle ear (ME). Plasma and MEF were collected for PK and MEF cultures performed to determine efficacy. Solithromycin administered at 150 mg/kg of body weight/day resulted in Cmax and AUC0-24 values of 2.2 μg/ml and 27.4 μg · h/ml in plasma and 1.7 μg/ml and 28.2 μg · h/ml in extracellular MEF on day 1. By day 3, Cmax and AUC0-24 values had increased to 4.5 μg/ml and 54 μg · h/ml in plasma and 4.8 μg/ml and 98.6 μg · h/ml in extracellular MEF. For NTHi EOM, three isolates with MIC/minimal bactericidal concentration (MBC) ratios of 0.5/1 μg/ml (isolate BCH1), 2/2 μg/ml (isolate BMC1247C), and 4/4 μg/ml (isolate BMC1213C) were selected. The MEF of >85% of animals infected with BCH1 and BMC1247C was sterilized. For NTHi BMC1213, >85% of MEF cultures remained positive. For S. pneumoniae EOM, 3 isolates with MIC/MBC ratios of 0.06/0.125 μg/ml (S. pneumoniae 331), 0.125/1 μg/ml (S. pneumoniae CP-645 [MLSB phenotype]), and 0.5/2 μg/ml (CP-712 [mefA subclass mefA resistance]) were selected. Solithromycin sterilized MEF in 100% of animals infected with S. pneumoniae 331 and S. pneumoniae CP-645. ME infection persisted in 60% of animals infected with CP-712. In a model of EOM, solithromycin sterilized MEF in >85% of animals challenged with NTHi with an MIC of ≤2 μg/ml and 100% of ME infected with S. pneumoniae with an MIC of ≤0.125 μg/ml.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27401563      PMCID: PMC4997842          DOI: 10.1128/AAC.00863-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Distribution of subclasses mefA and mefE of the mefA gene among clinical isolates of macrolide-resistant (M-phenotype) Streptococcus pneumoniae, viridans group streptococci, and Streptococcus pyogenes.

Authors:  Carmen Ardanuy; Fe Tubau; Josefina Liñares; María Angeles Domínguez; Román Pallarés; Rogelio Martín
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

2.  Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.

Authors:  J Gordon Still; Jennifer Schranz; Thorsten P Degenhardt; Drusilla Scott; Prabhavathi Fernandes; Maria J Gutierrez; Kay Clark
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.

Authors:  Shannon D Putnam; Mariana Castanheira; Gary J Moet; David J Farrell; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2010-04       Impact factor: 2.803

Review 4.  Appropriate treatment of acute otitis media in the era of antibiotic resistance.

Authors:  Ron Dagan
Journal:  Paediatr Drugs       Date:  2010-06-29       Impact factor: 3.022

5.  Efficacy of linezolid in experimental otitis media.

Authors:  S I Pelton; M Figueira; R Albut; D Stalker
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

6.  Effect of antimicrobial treatment of acute otitis media on the daily disappearance of middle ear effusion: a placebo-controlled trial.

Authors:  Terhi Tapiainen; Tiia Kujala; Marjo Renko; Petri Koivunen; Tero Kontiokari; Aila Kristo; Tytti Pokka; Olli-Pekka Alho; Matti Uhari
Journal:  JAMA Pediatr       Date:  2014-07       Impact factor: 16.193

7.  Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).

Authors:  Carlos M Barrera; Analia Mykietiuk; Hristo Metev; Mimi Floarea Nitu; Najumuddin Karimjee; Pablo Alexis Doreski; Ismail Mitha; Cristina Mihaela Tanaseanu; Joseph McDermott Molina; Yuri Antonovsky; Dirkie Johanna Van Rensburg; Brian H Rowe; Jose Flores-Figueroa; Barbara Rewerska; Kay Clark; Kara Keedy; Amanda Sheets; Drusilla Scott; Gary Horwith; Anita F Das; Brian Jamieson; Prabhavathi Fernandes; David Oldach
Journal:  Lancet Infect Dis       Date:  2016-02-05       Impact factor: 25.071

8.  A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition.

Authors:  Yoshiki Kobayashi; Hiroo Wada; Christos Rossios; Dai Takagi; Manabu Higaki; Shin'ichiro Mikura; Hajime Goto; Peter J Barnes; Kazuhiro Ito
Journal:  J Pharmacol Exp Ther       Date:  2013-01-28       Impact factor: 4.030

9.  Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents.

Authors:  Daniel Gonzalez; Debra L Palazzi; Leena Bhattacharya-Mithal; Amira Al-Uzri; Laura P James; John Bradley; Natalie Neu; Theresa Jasion; Christoph P Hornik; P Brian Smith; Daniel K Benjamin; Kara Keedy; Prabhavathi Fernandes; Michael Cohen-Wolkowiez
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.938

10.  In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrations.

Authors:  Elena De Vecchi; Lucia Nicola; Monica Larosa; Lorenzo Drago
Journal:  BMC Microbiol       Date:  2008-01-29       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.